Zydus receives USFDA’s final approval for Lacosamide injection
NEW DELHI: Ahmedabad-based Zydus Lifesciences Limited said that it has received the final approval from the United States Food and Drug Administration (USFDA) to market Lacosamide injection, used to treat partial-onset seizures on June 30.
Lacosamide injection also used with other medicines to treat primary generalised tonic-clonic seizures.
“It acts on the Central Nervous System (CNS) to reduce the number and severity of seizures. The drug will be manufactured at the group’s injectables manufacturing facility at Jarod, India,” Zydus lifesciences said.
As per IQVIA, Lacosamide Injection has a market size of $50 million.
